DTX3 and diffuse large B-cell lymphoma: Non-selective drugs simultaneously targeting DTX3 and DTX1 might be even more efficient and beneficial for DLBCL patients since DTX1 may also have oncogenic functions in DLBCL and forms distinct heterodimers with DTX3L.